Lioudis M, Zhou X, Davenport E, Nunna S, Krasa HB, Oberdhan D, Fernandes AW. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC Neurol. 2023 Jun 22;24:182. doi: 10.1186/s12882-023-03247-6
Browning JC, Cartwright M, Thorla, Jr. I, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A patient-centered perspective of molluscum contagiosum as reported by B-SIMPLE4 clinical trial patients and caregivers: global impression of change and exit interview substudy results. Am J Clin Dermatol. 2023 Jan;24(1):119-33. doi: 10.1007/s40257-022-00733-9
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021 May 24;21(1):208. doi: 10.1186/s12883-021-02237-1
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021 May 24;21(1):208. doi: 10.1186/s12883-021-02237-1
Hollis K, Proctor C, McBride D, Balp MM, McLeod L, Hunter S, Tian H, Khalil S, Maurer M. Comparison of Urticaria Activity Score over 7 days (UAS7) values obtained from once-daily and twice daily versions: results from the ASSURE-CSU study. Am J Clin Dermatol. 2018 Apr;19(2):267-74. doi: 10.1007/s40257-017-0331-8
Matlis S, Boric K, Chu CJ, Kramer MA. Robust disruptions in electroencephalogram cortical oscillations and large-scale functional networks in autism. BMC Neurol. 2015 Jun 27;15:97. doi: 10.1186/s12883-015-0355-8.
Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.
Hunt SM, McKenna SP, Doward LC. Preliminary report on the development of a disease-specific instrument for assessing quality of life of adults with growth hormone deficiency. Acta Endocrinol. 1993 Jun 1;128(Suppl 2):37-40.